Peer-reviewedCC BY-NC-ND 4.0Scientific Reports
Efficacy and safety of a cetuximab biosimilar compared with Erbitux in patients with RAS wild-type metastatic colorectal cancer
Related
- Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial
- IPO5 contributes to cetuximab resistance in colorectal cancer by modulating Ras signaling
- Comparing the efficacy and safety of raltitrexed combined with irinotecan administered in different dose-schedule patterns for the second-line treatment of metastatic colorectal cancer: an exploratory, observational post hoc analysis from the prospective SALLY registry cohort.
- Efficacy and safety of regorafenib plus PD-1/PD-L1 inhibitors for metastatic colorectal cancer: a systematic review and meta-analysis
- Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis
BibTeX
@article{rezvani2026efficacy,
title = {{Efficacy and safety of a cetuximab biosimilar compared with Erbitux in patients with RAS wild-type metastatic colorectal cancer}},
author = {Hamid Rezvani and Alireza Rezvani and Abolghasem Allahyari and Mojtaba Ghadiany and Ali Esfahani and Seyed Mohammad Reza Mortazavizadeh and Valiollah Mehrzad and Nastaran Khodakarim and Mojtaba Gorji and Mehran Sharifi and Hadi Mohammad Doost and Mehran Hosseinzadeh and Aliraza Bari and Babak Nejati and Alireza Sadeghi and Seyed Hadi Chavoshi and Amirabbass Nekouee and Mohsen Razavi and Ali Hajigholami and Behjat Kalantari and Adnan Khosravi and Ali Darakhshandeh and Sajjad Ataei Azimi and Alireza Abrishami and Sahar Tavakkoli Shiraji and Araz Sabzvari and Sina Salari and Hamidreza Kafi},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-75181-0},
url = {https://www.nature.com/articles/s41598-026-75181-0},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Efficacy and safety of a cetuximab biosimilar compared with Erbitux in patients with RAS wild-type metastatic colorectal cancer
AU - Hamid Rezvani
AU - Alireza Rezvani
AU - Abolghasem Allahyari
AU - Mojtaba Ghadiany
AU - Ali Esfahani
AU - Seyed Mohammad Reza Mortazavizadeh
AU - Valiollah Mehrzad
AU - Nastaran Khodakarim
AU - Mojtaba Gorji
AU - Mehran Sharifi
AU - Hadi Mohammad Doost
AU - Mehran Hosseinzadeh
AU - Aliraza Bari
AU - Babak Nejati
AU - Alireza Sadeghi
AU - Seyed Hadi Chavoshi
AU - Amirabbass Nekouee
AU - Mohsen Razavi
AU - Ali Hajigholami
AU - Behjat Kalantari
AU - Adnan Khosravi
AU - Ali Darakhshandeh
AU - Sajjad Ataei Azimi
AU - Alireza Abrishami
AU - Sahar Tavakkoli Shiraji
AU - Araz Sabzvari
AU - Sina Salari
AU - Hamidreza Kafi
PY - 2026
DA - 2026/10/14
JO - Scientific Reports
DO - 10.1038/s41598-026-75181-0
UR - https://www.nature.com/articles/s41598-026-75181-0
SN - 2045-2322
ER -